Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

4.720 -0.080 (-1.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,545,610
Open 4.730
Bid (Size) 4.720 (30)
Ask (Size) 4.790 (4)
Prev. Close 4.800
Today's Range 4.620 - 4.790
52wk Range 4.305 - 20.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-66.29%
-66.29%
1 Month
-22.37%
-22.37%
3 Month
-10.10%
-10.10%
6 Month
-45.62%
-45.62%
1 Year
-60.63%
-60.63%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
From The Rosen Law Firm PA
Via GlobeNewswire
Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
From Faruqi & Faruqi LLP
Via GlobeNewswire
Shareholder Rights Attorneys Robbins LLP Reminds VERV Stockholders of the Opportunity to Lead the Verve Therapeutics, Inc. Class Action
From Robbins LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Verve Therapeutics, Inc. (NASDAQ: VERV); Investors with Losses Encouraged to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
From The Rosen Law Firm PA
Via GlobeNewswire
VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, Verve, and MongoDB and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.